UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

File	by the Registrant ⊠ Filed by a Party other than the Registrant □
Che	k the appropriate box:
	Preliminary Proxy Statement
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
	Definitive Proxy Statement
\boxtimes	Definitive Additional Materials
	Soliciting Material Pursuant to §240.14a-12
	AngioDynamics, Inc. (Name of Registrant as Specified In Its Charter) angiodynamics
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Pay	nent of Filing Fee (check the appropriate box):
X	No fee required
	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11
(1)	Title of each class of securities to which transaction applies:
(2)	Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):		
d maximum aggregate value of transaction:		
e paid:		
d previously with preliminary materials.		
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid asly. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Previously paid:		
chedule or Registration Statement No.:		
arty:		
led:		



ANGIODYNAMICS, INC. 14 Plaza Drive Latham, NY 12110 ATTN: STEPHEN A. TROWBRIDGE

Your Vote Counts!

ANGIODYNAMICS, INC.

2022 Annual Meeting Vote by November 02, 2022 11:59 PM ET



You invested in ANGIODYNAMICS, INC. and it's time to vote!
You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on November 03, 2022.

Get informed before you vote

View the Notice & Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 20, 2022. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



^{*}Please check the meeting materials for any special requirements for meeting attendance.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items			
Nominees:		⊘ For	
To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accounting firm for the fiscal year ending May 31, 2023.			
Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers.			
Vote on the approval of the proposal to increase the number of shares available for issuance under the AngioDynamics, Inc. 2020 Equity Incentive Plan			
Vote on the approval of the proposal to increase the number of shares available for issuance under the AngioDynamics, Inc. Employee Stock Purchase Plan			
	Proposal to elect two Class I directors, for Nominees: 01 Dennis Meteny To ratify the appointment of Deloitte & accounting firm for the fiscal year ending. Say-on-Pay - An advisory vote on the approval of the proposal to AngioDynamics, Inc. 2020 Equity Incentity.	Proposal to elect two Class I directors, for a term of three years; Nominees: 01 Dennis Meteny 02 Michael Tarnoff To ratify the appointment of Deloitte & Touche LLP as AngioDynamics, Inc. independent registered public accounting firm for the fiscal year ending May 31, 2023. Say-on-Pay - An advisory vote on the approval of compensation of our named executive officers. Vote on the approval of the proposal to increase the number of shares available for issuance under the AngioDynamics, Inc. 2020 Equity Incentive Plan Vote on the approval of the proposal to increase the number of shares available for issuance under the	

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".